Oramed Pharmaceuticals Files Definitive Proxy Statement

TL;DR

ORAM proxy filing out - shareholders vote soon on company direction.

AI Summary

Oramed Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEF 14A) on June 20, 2024, for its fiscal year ending December 31, 2024. The filing concerns the solicitation of proxies for its upcoming annual meeting. The company, previously known as Integrated Security Technologies, Inc. and Iguana Ventures Ltd, is headquartered in New York.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the company's annual meeting, influencing voting decisions on corporate governance and strategy.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or material events.

Key Numbers

• 20240620 — Filing Date (Date the DEF 14A was filed with the SEC.)
• 20240801 — Report Date (The period this filing is reporting on.)

Key Players & Entities

• ORAMED PHARMACEUTICALS INC. (company) — Registrant
• 20240620 (date) — Filing Date
• 20240801 (date) — Report Date
• 1185 AVENUE OF THE AMERICAS, 3RD FLOOR (address) — Business Address
• Integrated Security Technologies, Inc. (company) — Former Company Name
• IGUANA VENTURES LTD (company) — Former Company Name

FAQ

Filing Documents

• ea0207614-def14a_oramed.htm (DEF 14A) — 316KB
• image_001.jpg (GRAPHIC) — 30KB
• image_002.jpg (GRAPHIC) — 28KB
• image_003.jpg (GRAPHIC) — 726KB
• image_004.jpg (GRAPHIC) — 580KB
• 0001213900-24-054007.txt ( ) — 2198KB

From the Filing

DEF 14A 1 ea0207614-def14a_oramed.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON , D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e) (2) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 ORAMED PHARMACEUTICALS INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 ORAMED PHARMACEUTICALS INC. 1185 Avenue of the Americas, Third Floor New York, New York 10036 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024 To Our Stockholders: You are cordially invited to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of Oramed Pharmaceuticals Inc. (the “Company,” “we,” “us,” or “our”). The Annual Meeting will be held at our Israeli office, located at 20 Mamilla Avenue, Jerusalem, 9414904, Israel, on August 1, 2024, at 4:00 p.m. (Israel time). We intend to hold the annual meeting for the following purposes: 1. To re-elect seven directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; 2. To consider and approve, by a non-binding advisory vote, the compensation of our Named Executive Officers as described in the accompanying proxy statement; 3. To ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited (the “Independent Auditors”), as the independent registered public accounting firm of the Company for the 2024 fiscal year; and 4. To transact any other business as may properly come before the Annual Meeting or any adjournments thereof. Our Board of Directors has fixed the close of business on June 12, 2024, as the record date for the determination of stockholders entitled to notice of and to vote at the Annual Meeting and at any adjournments or postponement thereof. All stockholders are invited to attend the Annual Meeting in person. Whether or not you plan to attend the Annual Meeting, please complete, date and sign the enclosed proxy card and return it in the enclosed envelope, as promptly as possible. If you attend the Annual Meeting, you may withdraw the proxy and vote in person. If you have any questions regarding the completion of the enclosed proxy card or would like directions to the Annual Meeting, please call 844-967-2633. You may also find directions at https://www.oramed.com/investors/governance-documents/annual-shareholder-meeting . By Order of the Board of Directors, Nadav Kidron President, Chief Executive Officer and Director New York, New York June 19, 2024 PROXY OF ORAMED PHARMACEUTICALS INC. ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024 The enclosed proxy is solicited on behalf of the Board of Directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company,” “we,” “us,” or “our”), for use at the Annual Meeting of Stockholders to be held on August 1, 2024, at 4:00 p.m. (Israel time) (the “Annual Meeting”), or at any adjournment or postponement thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders. The Annual Meeting will be held at our Israeli office, located at 20 Mamilla Avenue, Jerusalem, 9414904, Israel. We intend to first mail this proxy statement and our annual report to stockholders (the “Annual Report”) for the fiscal year ended December 31, 2023 (“Fiscal 2023”), as well as the enclosed proxy card, on or about June 19, 2024, to all stockholders entitled to vote at the Annual Meeting. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The proxy statement, proxy card and Annual Report are also available at https://www.oramed.com/investors/governance-documents/annual-shareholder-meeting Stockholders may also obtain additional paper or e-mail copies of these materials by writing to Oramed Pharmaceuticals Inc., 1185 Avenue of the Americas, Third Floor, New York, New York 10036, attention: Secretary, or by sending an e-mail to info@oramed.com. QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING Why am I receiving these mate

View Full Filing

View this DEF 14A filing on SEC EDGAR